Ivabradine Macleods Pharma Uk

Ivabradine, the active ingredient in Ivabradine Macleods Pharma Uk, is an If channel inhibitor presented as a oral tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradine Macleods Pharma Uk as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is used to manage conditions related to cardiac ischemia and heart failure by selectively lowering heart rate. - Chronic stable angina pectoris: reduces frequency of angina attacks by decreasing myocardial oxygen demand. - Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and may reduce hospitalisation by lowering heart rate. - Exercise intolerance in heart failure: enhances functional capacity through heart‑rate reduction.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Heart block (advanced AV block). - Worsening heart failure. - Severe visual disturbances (persistent photopsia). - Hypotension leading to syncope.

Ivabradine requires careful patient assessment and monitoring. - Dose adjustment: reduce dose in patients with moderate hepatic impairment. - Avoid use in severe bradycardia (resting HR <50 bpm) or sick sinus syndrome. - Monitor heart rate regularly to maintain target range. - Caution with concomitant CYP3A4 inhibitors, which may increase plasma levels. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ivabradine may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations. - Concomitant bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Verapamil or diltiazem (CYP3A4 inhibitors): can increase ivabradine exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may lower ivabradine effectiveness. - Other antiarrhythmics (e.g., amiodarone): require heart‑rate monitoring. - Antihypertensives: may have additive effects on heart rate and require dose adjustments.